HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

EDDA Healthcare and Technology / Equity Capital Markets

With the continuous improvement of science and technology and the development of healthcare industry, there has been new expectations on digitalization and intelligence. On July 9, 2021, <a href="https://www.smartkarma.com/entities/edda-healthcare-and-technology-holding-limited" target="_blank" data-smartkarma-citation="entities:33805:1" rel="noopener">EDDA Healthcare and Technology (EDD HK),</a> a pioneer in providing innovative intelligent solutions enabling precision surgery, submitted its prospectus to the HKEX for an IPO on the main board. This insight mainly analyzed the industry characteristics, the business and the concerns of the Company.

With the continuous improvement of science and technology and the development of healthcare industry, there has been new expectations on digitalization and intelligence. On July 9, 2021, EDDA Healthcare and Technology (EDD HK), a pioneer in providing innovative intelligent solutions enabling precision surgery, submitted its prospectus to the HKEX for an IPO on the main board. This insight mainly analyzed the industry characteristics, the business and the concerns of the Company.

Pre-IPO EDDA Healthcare and Technology - Concerns Are on Commercialization

Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

<a href="https://www.smartkarma.com/entities/edda-healthcare-and-technology-holding-limited" target="_blank" data-smartkarma-citation="entities:33805:1" rel="noopener">EDDA Healthcare and Technology (EDD HK)</a> is a provider of intelligent solutions (involving surgical robots and precision surgery planning) to perform precision surgery. The company’s core products are its surgical robot series: IQQA-Guide and a precision surgery planning software: IQQA-3D.EDDA Healthcare has filed for an IPO in the Hong Kong Stock Exchange and according to Bloomberg, the company plans to raise around US$300m through the IPO. The company is backed by SoftBank Group.EDDA Healthcare has over 15 years of experience in providing precision surgery solutions. The precision surgery planning market shows strong growth prospects which would allow the company to continue generating strong revenues. Moreover, the company’s latest introduction of a surgical robot is likely to become a stronger revenue driver in future given that China’s surgical robot industry is still in a nascent stage and is rapidly expanding.

EDDA Healthcare and Technology (EDD HK) is a provider of intelligent solutions (involving surgical robots and precision surgery planning) to perform precision surgery. The company’s core products are its surgical robot series: IQQA-Guide and a precision surgery planning software: IQQA-3D.EDDA Healthcare has filed for an IPO in the Hong Kong Stock Exchange and according to Bloomberg, the company plans to raise around US$300m through the IPO. The company is backed by SoftBank Group.EDDA Healthcare has over 15 years of experience in providing precision surgery solutions. The precision surgery planning market shows strong growth prospects which would allow the company to continue generating strong revenues. Moreover, the company’s latest introduction of a surgical robot is likely to become a stronger revenue driver in future given that China’s surgical robot industry is still in a nascent stage and is rapidly expanding.

EDDA Healthcare IPO: Surgical Robots Show Strong Growth Prospects

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

EDDA Healthcare and Technology Holding Limited (EDDA), offers innovative intelligent solutions to enable precision surgery. It aims to raise up to US$300m in its Hong Kong IPO.EDDA provides a precision surgery solution portfolio, consisting of surgical robots series IQQA-Guide, and a portfolio of precision surgery planning software, including IQQA-3D. It has also established a 3D precision surgery digital solution cloud platform in China (IQQA Cloud Platform) which integrates functions of IQQA-3D and enables physicians to collaborate remotely in real time.Through IQQA-3D and IQQA Cloud Platform, it has assisted in over 70,000 precision surgeries in China across 60 of the top 100 hospitals. Its precision surgery planning software is also registered in the United states. It is the largest player in China’s precision surgical planning market for thoracic and abdominal applications, with over a one-third market share, in terms of surgical cases completed in 2020, according to Frost &amp; Sullivan.

EDDA Healthcare and Technology Holding Limited (EDDA), offers innovative intelligent solutions to enable precision surgery. It aims to raise up to US$300m in its Hong Kong IPO.EDDA provides a precision surgery solution portfolio, consisting of surgical robots series IQQA-Guide, and a portfolio of precision surgery planning software, including IQQA-3D. It has also established a 3D precision surgery digital solution cloud platform in China (IQQA Cloud Platform) which integrates functions of IQQA-3D and enables physicians to collaborate remotely in real time.Through IQQA-3D and IQQA Cloud Platform, it has assisted in over 70,000 precision surgeries in China across 60 of the top 100 hospitals. Its precision surgery planning software is also registered in the United states. It is the largest player in China’s precision surgical planning market for thoracic and abdominal applications, with over a one-third market share, in terms of surgical cases completed in 2020, according to Frost &amp; Sullivan.

EDDA Healthcare Pre-IPO - RoboDoc - Has Been Around for a While but Is Just Getting the Robo Going

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

EDDA Healthcare and Technology (EDD HK)

Pre-IPO EDDA Healthcare and Technology - Concerns Are on Commercialization

This article mainly analyzed EDDA Healthcare and Technology in terms of the industry characteristics, the business, the commercialization outlook,...

Xinyao (Criss) Wang

EDDA Healthcare IPO: Surgical Robots Show Strong Growth Prospects

EDDA's launch of a surgical robot is likely to become a stronger revenue driver in future given that China’s surgical robot industry is still in a...

Shifara Samsudeen, ACMA, CGMA

EDDA Healthcare Pre-IPO - RoboDoc - Has Been Around for a While but Is Just Getting the Robo Going

EDDA Healthcare and Technology Holding Limited (EDDA), offers innovative intelligent solutions to enable precision surgery. It aims to raise up to...

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)